Tyvaso DPI

About United Therapeutics

Founded on a personal mission to treat pulmonary arterial hypertension, United Therapeutics has grown into a diversified, multi-platform biotech leader with a $26B+ market cap. The company successfully commercializes a portfolio of PAH therapies while aggressively pursuing its 'Mozart' moonshot to create an unlimited supply of transplantable organs. This dual strategy balances near-term financial strength from its rare disease franchise with transformative, long-term value creation in organ manufacturing and regenerative medicine.

About MannKind Corp

MannKind Corporation has evolved from a development-stage enterprise into a multi-product biopharmaceutical company with a core mission of transforming chronic disease management through innovative, patient-centric inhaled solutions. Its competitive moat is anchored in the proprietary Technosphere® drug delivery platform, which has enabled the commercialization of Afrezza® and underpins a diversified portfolio and partnership strategy. The company is now demonstrating strong commercial execution, with FY2025 revenues reaching $349 million, driven by growth in its core products and strategic acquisitions like scPharmaceuticals.

Therapeutic Areas